Spark Plug Pipe

HENDERSON, NV / ACCESSWIRE / November 19, 2018 / Every day, more than 115 people in the United States die after overdosing on opioids. The misuse of and addiction to opioids – including prescription pain relievers, heroin, and synthetic opioids such as fentanyl is a serious national crisis that affects public health as well as social and economic welfare. The Centers for Disease Control and Prevention estimates that the total “economic burden” of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement. Some see marijuana and CBD as potential solution to the problem, some have pinpointed non-invasive therapies and below we’ve outlined a few companies that may be the answer to this crisis.

The first on our list is Endonovo Therapeutics, Inc. (ENDV). The company has an extremely promising non-invasive pain reduction device that delivers targeted pulsed ElectroMagnetic Field (tPEMF) therapies. Their patented process uses proprietary technology to reduce pain, swelling and inflammation. One of their new therapies focuses on treating orthopedic, sports and on the job injuries, ORTHOHALO. This particular therapy could be an answer to opioids that are prescribed when patients suffer the same injuries.

According to the Substance Abuse and Mental Health Services Administration, over 22% of people who end up abusing prescription painkillers got them from a doctor. That’s in addition to the more than 50% of people whose prescription drug misuse started because they got it from friends or family members for free. That adds up to well over 72% of prescription drug abusers whose prescription drug abuse started because they got pills from someone they trusted.

ENDV would be a great place to start if you’re looking to research potential companies that could be the answer to the opioid crisis.

Companies to put on your radar include: Endonovo Therapeutics, Inc. (ENDV), Aurora Cannabis (ACB), Aphria, Inc. (NYSE:APHA), INSYS Therapeutics, Inc. (NASDAQ:INSY), and CV Sciences, Inc. (OTCQB:CVSI).

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $13.84M Share Price: $0.037

Last week, Endonovo Therapeutics (ENDV) announced the expansion of their suite of complimentary products with the ORTHOHALO?. ORTHOHALO? is an easy-to-use, non-invasive device delivering targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation. There are no known side effects and no potential for overdose or dependency.

ORTHOHALO? is a new product line designed to provide personalized treatments for orthopedic, sports, and on the job injuries. ORTHOHALO? aims to accomplish this by providing each patient a customized application that can be used in conjunction with a wide range of bracing, splint, and other products. ORTHOHALO? is the only PEMF device that can be used to provide around-the-clock pain management and edema control for orthopedic patients.

Aurora Cannabis, Inc. (ACB)

Market Cap: $7.00B Share Price: $7.29

Aurora Cannabis Inc. (ACB), just announced the official opening of its latest high-tech cannabis production facility in Lachute, Quebec; the company is calling it “Eau.”

At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora’s second production facility in Quebec , the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec.

Aphria, Inc. (APHA)

Market Cap: $3.18B Share Price: $12.31

Aphria Inc. (APHA) announced an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT’s QuickStrip? innovative, proprietary delivery technology for both medical and adult-use cannabis market.

INSYS Therapeutics, Inc. (INSY)

Market Cap: $567.97M Share Price: $7.65

NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently reported financial results for its third quarter ended Sept. 30, 2018. The company achieved net revenue of $18.3 million in the third quarter of 2018.

CV Sciences, Inc. (CVSI)

Market Cap: $489.39M Share Price: $5.12

CVSI announced that it will be a Title Sponsor of the 25th anniversary of HIACON Conference on November 2-5, in Los Angeles, California. Produced by the Hemp Industries Association (HIA), HIACON will bring together over 400 attendees (cultivators, stakeholders, buyers), more than 55 speakers and industry thought leaders, and many other hemp and CBD sponsors to the Hilton Los Angeles Airport Hotel.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Regal Consulting, LLC